Literature DB >> 30201107

Effect of Cigarette Smoking on Risk for Adverse Events in Patients With Heart Failure and Preserved Ejection Fraction.

Pratik B Sandesara1, Ayman Samman-Tahhan1, Matthew Topel1, Sanjay Venkatesh2, Wesley T O'Neal3.   

Abstract

Smoking is an important risk factor in the development of heart failure with preserved ejection (HFpEF), and previous reports have identified smoking as a significant predictor of death in this population. However, the relation between smoking and heart failure-specific outcomes has not been examined in patients with HFpEF. This analysis included 1,717 patients (mean age = 71 ± 10 years; 50% men; 78% white) with HFpEF enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial from the Americas. Smoking was ascertained by self-reported history and categorized as never, former, or current. Multivariable Cox regression was used to examine the risk of hospitalization for heart failure, death, and cardiovascular death across smoking categories. There were 116 current smokers (7%), 871 former smokers (51%), and 729 never smokers (42%) in this analysis. Current smoking was associated with an increased risk of hospitalization for heart failure (never: hazard ratio [HR] 1.0; former: HR 1.25, 95% confidence interval [CI] 0.99 to 1.57; current: HR 1.68, 95% CI 1.08 to 2.61), death (never: HR 1.0; former: HR 1.02, 95% CI 0.81 to 1.29; current: HR 1.82, 95% CI 1.19 to 2.78), and cardiovascular death (never: HR 1.0; former: HR 1.00, 95% CI 0.74 to 1.35; current: HR 1.85, 95% CI 1.09 to 3.24) compared with former or never smokers in a multivariable model adjusted for cardiovascular risk factors. A similar increased risk of hospitalization for heart failure (former: HR 1.0; current: HR 1.54, 95% CI 1.01, 2.36), death (former: HR 1.0; current: HR 1.81, 95% CI 1.19, 2.75), and cardiovascular death (former: HR 1.0; current: HR 1.76, 95% CI 1.04, 2.98) was observed for current smokers when we limited the analysis to those with a history of smoking. In conclusion, current smoking is associated with an increased risk for adverse outcomes in HFpEF, including hospitalization for heart failure. Smoking cessation strategies possibly have a role to reduce the risk for adverse cardiovascular outcomes in patients with HFpEF.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30201107      PMCID: PMC6225999          DOI: 10.1016/j.amjcard.2018.04.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

2.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.

Authors:  Stuart J Pocock; Cono A Ariti; John J V McMurray; Aldo Maggioni; Lars Køber; Iain B Squire; Karl Swedberg; Joanna Dobson; Katrina K Poppe; Gillian A Whalley; Rob N Doughty
Journal:  Eur Heart J       Date:  2012-10-24       Impact factor: 29.983

3.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

4.  Acute hemodynamic effects of cigarette smoking in man assessed by systolic time intervals and echocardiography.

Authors:  B D Rabinowitz; K Thorp; G L Huber; W H Abelmann
Journal:  Circulation       Date:  1979-10       Impact factor: 29.690

5.  Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction.

Authors:  Jennifer E Ho; Asya Lyass; Douglas S Lee; Ramachandran S Vasan; William B Kannel; Martin G Larson; Daniel Levy
Journal:  Circ Heart Fail       Date:  2012-12-27       Impact factor: 8.790

6.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Authors:  Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

7.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

Review 9.  The pathophysiology of cigarette smoking and cardiovascular disease: an update.

Authors:  John A Ambrose; Rajat S Barua
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

Review 10.  New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.

Authors:  Amresh Raina; Manreet Kanwar
Journal:  Curr Heart Fail Rep       Date:  2014-12
View more
  2 in total

1.  Demystifying Smoker's Paradox: A Propensity Score-Weighted Analysis in Patients Hospitalized With Acute Heart Failure.

Authors:  Suhail A Doi; Nazmul Islam; Kadhim Sulaiman; Alawi A Alsheikh-Ali; Rajvir Singh; Awad Al-Qahtani; Nidal Asaad; Khalid F AlHabib; Ibrahim Al-Zakwani; Mohammed Al-Jarallah; Wael AlMahmeed; Bassam Bulbanat; Nooshin Bazargani; Haitham Amin; Ahmed Al-Motarreb; Husam AlFaleh; Prashanth Panduranga; Abdulla Shehab; Jassim Al Suwaidi; Amar M Salam
Journal:  J Am Heart Assoc       Date:  2019-11-29       Impact factor: 5.501

2.  Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors.

Authors:  Kerryn W Reding; Richard K Cheng; Alexi Vasbinder; Roberta M Ray; Ana Barac; Charles B Eaton; Nazmus Saquib; Aladdin H Shadyab; Michael S Simon; Dale Langford; Mary Branch; Bette Caan; Garnet Anderson
Journal:  JACC CardioOncol       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.